Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 131

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 131
---
 12,595 Other investments10,908 36,726 Deferred income taxes, net72 214 Other assets6,924 6,392 Total assets$941,774 $787,216 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities:Accounts payable$5,233 $2,427 Accrued liabilities27,906 12,467 Income tax payable1,199 — Deferred revenue   1,278 1,222 Current contingent liabilities206 256 Current operating lease liabilities1,266 403 Current finance lease liabilities24 7 Total current liabilities37,112 16,782 Long-term deferred revenue2,246 1,444 Long-term contingent liabilities3,475 2,942 Long-term operating lease liabilities5,815 5,755 Deferred income taxes, net32,524 31,622 Other long-term liabilities30,163 27,758 Total liabilities111,335 86,303 Commitments and contingenciesStockholders’ equity:      Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2024 and 2023— — Common stock, $0.001 par value; 60,000 shares authorized; 19,106 and 17,556 shares issued and outstanding at December 31, 2024 and 2023, respectively20 18 Additional paid-in capital337,377 198,696 Accumulated other comprehensive loss(5,942)(817)Retained earnings498,984 503,016 Total stockholders’ equity830,439 700,913       Total liabilities and stockholders’ equity $941,774 $787,216 

See accompanying notes to these consolidated financial statements.

60

LIGAND PHARMACEUTICALS INCORPORATED

CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

 Year Ended December 31,202420232022Revenues and other income:Revenue from intangible royalty assets$95,329 $83,910 $72,527 Income from financial royalty assets13,444 1,049 385 Royalties108,773 84,959 72,912 Captisol30,883 28,372 104,495 Contract revenue and other income27,477